![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Jinan Tantu Chemicals Gefapixant Citrate](https://www.pharmacompass.com/image/flap/jinan-guoding-gefapixant-citrate-desktop-headergif-99259.gif)
![Jinan Tantu Chemicals Gefapixant Citrate](https://www.pharmacompass.com/image/flap/jinan-guoding-gefapixant-citrate-mobgif-55805.gif)
Active Filter(s):
Details:
Lyfnua (gefapixant) is an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough or unexplained chronic cough in adults.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Lyfnua
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
MK-7264 (gefapixant), an investigational, orally administered, selective P2X3 receptor antagonist, is being developed for the potential treatment of refractory or unexplained chronic cough and was approved in Japan and Switzerland under the brand name Lyfnua®.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MK-7264
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Last week, the Japan Ministry of Health, Labor and Welfare (MHLW) approved LYFNUA® (gefapixant) Tablets 45 mg for adults with refractory or unexplained chronic cough.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Lyfnua
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
COUGH-1 and COUGH-2 are international Phase 3, randomized, double-blind, placebo-controlled, studies to evaluate the efficacy and safety of gefapixant in reducing cough frequency in adult participants with refractory or unexplained chronic cough.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MK-7264
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020